Emma works in close collaboration with both experts in different regulatory areas and the research coordinator at the agency. As part of the science to policy interactions, Emma is involved in enhancing academic understanding of the conditions, needs, and requirements of authorities to effectively apply research results. She also fosters increased understanding and interest within authorities regarding the conditions and needs for collaboration. Through her work, she aims to bridge the gap between public actors, industry, and academia, ensuring that research knowledge benefits society. She advocates for expanded collaboration beyond academic publications to address current and future challenges, promoting synergy and understanding across sectors to translate research investments into tangible societal benefits. In her work at the Swedish Chemicals Agency, she is also involved in the Toxicological Council, identifying new emerging risk chemicals.

Tim is an experienced scientist in in vitro assay development, bringing extensive knowledge in immunology and genomics from his Master of Science in Molecular Biotechnology and Ph.D. in Immunotechnology from Lund University. His expertise includes mechanistic and technical aspects of assay development. With a background in commercial sales in the biotech industry, he has a deep understanding of market needs and dynamics. He co-developed the GARD platform, a groundbreaking technology in the field, and holds a related patent, highlighting his innovative contributions to scientific research.

Eric is a director of chemical toxicology at AstraZeneca. Eric got his PhD in organic chemistry at the University of Kaiserslautern in Germany. In 1998, he moved to Sweden and worked as medicinal chemist at Active Biotech and Principal Scientist in the MedChem organization at AstraZeneca. He joined Mölnlycke Health Care in 2014 and led the Bioscience Team as Senior Manager. In 2023, he re-joined AstraZeneca in his current role. The main focus of Erics work is the safety assessment and design of new chemical compounds across various projects from early discovery to clinical phase. Eric is particularly interested in multi-omic aspects and their impact on early safety evaluation. Another area of interest is the structural toxicity assessment of new modalities and the translation into in vivo.

Patrik is a professor in environmental chemistry at Umeå University, focusing on development of computational and experimental methods to assess chemical hazards. His research emphasizes "smart substitution", replacing hazardous chemicals with safer alternatives. In 2025, he joined IVL Swedish Environmental Research Institute as Innovations Coordinator for Sustainable Chemistry and became Programme Director for Mistra SafeChem. He has served as Deputy Head of the Department of Chemistry at Umeå University and has played key roles in Swetox and is a member of the Toxikologiska Rådet. His widely cited work contributes to risk assessment, exposure modeling, and computational chemistry, driving advancements in chemical safety and environmental research.

Linus' research project is titled “A Novel Mechanism-Based Approach for Assessment of Developmental Toxicity of Endocrine Disruptors”. The project’s aim is to develop risk assessment methodology that utilizes mechanistic data from New Approach Methodologies (NAMs) to facilitate identification of developmental toxicity caused by endocrine disruptors (EDs), without using in vivo data. Linus’ research explores how Adverse Outcome Pathways (AOPs) can be used to connect mechanistic data from various NAMs to adverse outcomes, in order to predict adversity, and identifies challenges associated with this approach.

Anna’s research focuses on investigating the mechanisms of chemically induced acute, developmental, and subchronic neurotoxicity using various neuronal cell models. The usefulness of the cell models for risk assessment is evaluated by integrating in vitro data derived from the cell models with historic in vivo data from rat and observations from exposed human in predictions models. Risk assessment predictions are based on Integrated Approaches to Testing and Assessment (IATA), Adverse Outcome Pathways (AOP) and Physiologically-Based Toxicokinetic (PBTK) modeling. Anna has taken part in the EU-ToxRisk project, which generated three OECD reports on IATA case studies regarding plant protection products.